독서리서치레이더투자 프레임워크
로그인 / 회원가입
← 읽기로 돌아가기
뉴스주제 · 英矽智能与施维雅合作중대1 분 소요DisconfirmAI 편집부

Insilico Medicine and Servier Achieve First Milestone in AI-Driven R&D Collaboration, Triggering Undisclosed Payment

Video confirms that Insilico Medicine achieved the first R&D milestone in its multi-year collaboration with French pharmaceutical giant Servier. Using its proprietary Pharma.AI platform, Insilico completed target nomination for two oncology programs, triggering an undisclosed milestone payment from Servier. The collaboration, announced in early 2026, has a total value of up to $888 million.

2026-10-21 23:41 GMT+8

Insilico Medicine has published a video on its official channel confirming substantive progress in its multi-year, AI-driven research and development collaboration with French pharmaceutical company Servier. According to the video description, two oncology programs under this partnership have initiated and completed target nomination, marking the first R&D milestone achieved by Insilico using its proprietary Pharma.AI platform.

The attainment of this technical node directly triggered an undisclosed milestone payment from Servier to Insilico. The collaboration was announced in early 2026, covering multi-target oncology areas, with a total potential value of up to $888 million, including $32 million in upfront and near-term R&D payments. For readers tracking the commercialization of AI in drug discovery, this event provides direct evidence of a major pharmaceutical company making staged payments based on specific AI technical outputs.

출처

  • youtube.com↗
주제
로그인 / 회원가입
독서리서치레이더투자 프레임워크

英矽智能与施维雅合作

生成式AI药物研发公司英矽智能(Insilico Medicine)宣布,其与法国制药巨头施维雅(Servier)的合作已达成首个早期药物发现里程碑,触发一笔未披露金额的付款。该合作于2026年初启动,总价值高达8.88亿美元,旨在利用英矽…

2 단계1 건업데이트됨 2026-10-22 16:56

현재까지의 과정

  1. 2026-01-01英矽智能与施维雅宣布达成多年期AI驱动药物研发合作,总价值最高达8.88亿美元,含3200万美元首付款及近期研发付款。insilico.com ↗
  2. 2026-10-20英矽智能发布公告,确认在合作框架下完成两个肿瘤项目的靶点提名,并达成首个项目的早期药物发现里程碑,触发未披露金额的付款。www1.hkexnews.hk ↗

아직 해결되지 않은 문제

  • 施维雅支付的具体里程碑金额是多少?
  • 这两个肿瘤项目针对的具体靶点是什么?
  • AI生成的候选化合物在后续临床验证中的成功率如何?
전체 주제 읽기 →
리서치 계속하기 →